Epinephrine, also known as adrenaline, is a hormone involved in your body’s “fight or flight” response. Epinephrine is produced by the adrenal glands, located on top of each of your kidneys.

SAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect ...

Democratic mayoral nominee Zohran Mamdani said he would drop a Holocaust remembrance group’s definition of “antisemitism” if he becomes mayor — a turnaround in police that has some Jewish rights ...

Aquestive Therapeutics (NASDAQ:AQST), a biopharmaceutical company specializing in orally administered therapeutics, is garnering attention from investors and analysts alike as it approaches a critical ...

neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children (>15 kg) living with severe allergic reactions Alfresa ...

In September 2025, analysts highlighted that the FDA waived the advisory committee meeting for Aquestive Therapeutics’ New Drug Application for Anaphylm, a needle-free, orally delivered epinephrine ...

An inconclusive medical result refers to when the test’s outcome isn’t clearly positive or negative. In healthcare settings, this typically means that further testing or an alternative diagnostic tool ...

The AMD High Definition Audio Device is an important tool for sending audio through DisplayPort or HDMI connections. It is integrated into different AMD modules of graphic cards like the Radeon R-9 ...

Enbumyst, a bumetanide nasal spray, is FDA-approved for edema in CHF, hepatic, and renal diseases, offering outpatient treatment. The nasal spray bridges gaps between oral and IV diuretics, providing ...

Khadija Khartit is a strategy, investment, and funding expert, and an educator of fintech and strategic finance in top universities. She has been an investor, entrepreneur, and advisor for more than ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Gordon Scott has been an active investor and ...